What do systematic reviews say?

Betamethasone vs usual care

• Antenatal corticosteroids prior to planned caesarean at term for improving neonatal outcomes 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Betamethasone vs usual care

• Antenatal corticosteroids prior to planned caesarean at term for improving neonatal outcomes 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 942 participants
  Very low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.67 [0.96, 2.88]
  2 studies · 80 participants
  Low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 154 participants
  Very low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 543 participants
  Very low

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 13.84 [0.87, 219.76]
  1 study · 231 participants
  Very low

Dexamethasone vs betamethasone – maternal outcomes

The review found no eligible studies for this question.

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dexamethasone vs betamethasone – child outcomes

Dexamethasone showed no clear difference in neurodevelopmental disability at compared with betamethasone – child outcomes (moderate certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 1.02 [0.85, 1.22]
  2 studies · 1151 participants
  Moderate

Dexamethasone vs betamethasone – child outcomes

Dexamethasone showed no clear difference in visual impairment compared with betamethasone – child outcomes (low certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 8.15]
  1 study · 1227 participants
  Low

Dexamethasone vs betamethasone – child outcomes

Dexamethasone showed no clear difference in hearing impairment compared with betamethasone – child outcomes (moderate certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 1.16 [0.63, 2.16]
  1 study · 1227 participants
  Moderate

Dexamethasone vs betamethasone – child outcomes

Dexamethasone showed no clear difference in developmental delay –motor (mild, moderate or severe) compared with betamethasone – child outcomes (moderate certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 0.89 [0.66, 1.2]
  1 study · 1166 participants
  Moderate

Dexamethasone vs betamethasone – child outcomes

Dexamethasone showed no clear difference in intellectual impairment: developmental delay – cognitive or language… compared with betamethasone – child outcomes (moderate certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 0.97 [0.79, 1.2]
  1 study · 1161 participants
  Moderate

Dexamethasone vs betamethasone – child outcomes

Dexamethasone showed no clear difference in cerebral palsy compared with betamethasone – child outcomes (low certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 2.5 [0.97, 6.39]
  1 study · 1223 participants
  Low

Dexamethasone vs betamethasone – maternal outcomes

Dexamethasone showed no clear difference in chorioamnionitis compared with betamethasone – maternal outcomes (moderate certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 0.71 [0.48, 1.06]
  1 study · 1346 participants
  Moderate

Dexamethasone vs betamethasone – maternal outcomes

The review found no eligible studies for this question.

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dexamethasone vs betamethasone – maternal outcomes

Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).

• Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
  RR 0.63 [0.35, 1.13]
  2 studies · 1705 participants
  Moderate